JPWO2021158996A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021158996A5 JPWO2021158996A5 JP2022547802A JP2022547802A JPWO2021158996A5 JP WO2021158996 A5 JPWO2021158996 A5 JP WO2021158996A5 JP 2022547802 A JP2022547802 A JP 2022547802A JP 2022547802 A JP2022547802 A JP 2022547802A JP WO2021158996 A5 JPWO2021158996 A5 JP WO2021158996A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- nanoparticle
- tumor
- nanoparticles
- cationic lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 claims 33
- 108020004707 nucleic acids Proteins 0.000 claims 31
- 102000039446 nucleic acids Human genes 0.000 claims 31
- 150000007523 nucleic acids Chemical class 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 238000000034 method Methods 0.000 claims 12
- 239000002502 liposome Substances 0.000 claims 9
- -1 cationic lipid Chemical class 0.000 claims 8
- 150000002632 lipids Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229920002477 rna polymer Polymers 0.000 claims 8
- 125000002091 cationic group Chemical group 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 239000000232 Lipid Bilayer Substances 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 239000003960 organic solvent Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 201000010225 mixed cell type cancer Diseases 0.000 claims 2
- 208000029638 mixed neoplasm Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000003307 reticuloendothelial effect Effects 0.000 claims 2
- 238000004513 sizing Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000001351 cycling effect Effects 0.000 claims 1
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 claims 1
- 208000026144 diffuse midline glioma, H3 K27M-mutant Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 201000004341 pediatric supratentorial ependymoma Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000000310 rehydration solution Substances 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 208000015033 supratentorial ependymoma Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062970646P | 2020-02-05 | 2020-02-05 | |
| US62/970,646 | 2020-02-05 | ||
| US202062991404P | 2020-03-18 | 2020-03-18 | |
| US62/991,404 | 2020-03-18 | ||
| PCT/US2021/016925 WO2021158996A1 (en) | 2020-02-05 | 2021-02-05 | Rna-loaded nanoparticles and use thereof for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512707A JP2023512707A (ja) | 2023-03-28 |
| JPWO2021158996A5 true JPWO2021158996A5 (https=) | 2024-02-13 |
| JP2023512707A5 JP2023512707A5 (https=) | 2024-02-13 |
Family
ID=77200411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547802A Pending JP2023512707A (ja) | 2020-02-05 | 2021-02-05 | Ｒｎａ負荷ナノ粒子およびがんの治療のためのそれらの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230096704A1 (https=) |
| EP (1) | EP4099988A4 (https=) |
| JP (1) | JP2023512707A (https=) |
| WO (1) | WO2021158996A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3999034A4 (en) * | 2019-07-19 | 2023-08-23 | University Of Florida Research Foundation, Incorporated | Multilamellar rna nanoparticles |
| JP2024517287A (ja) | 2021-05-07 | 2024-04-19 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | Ｃａｒ ｔ細胞療法の方法 |
| CN113876691B (zh) * | 2021-09-26 | 2023-08-08 | 华中科技大学同济医学院附属协和医院 | 一种包载靶标lncRNA Pvt1纳米粒子的水凝胶及其制备方法和应用 |
| WO2023196232A1 (en) * | 2022-04-04 | 2023-10-12 | University Of Florida Research Foundation, Inc. | Method of characterizing tumors |
| WO2025207807A1 (en) * | 2024-03-27 | 2025-10-02 | The University Of Florida Research Foundation, Inc. | Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897269A (en) * | 1984-09-24 | 1990-01-30 | Mezei Associates Limited | Administration of drugs with multiphase liposomal delivery system |
| IN190388B (https=) * | 1997-10-01 | 2003-07-26 | Biomira Usa Inc | |
| WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| ITRM20120480A1 (it) * | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| CN107073028A (zh) * | 2013-12-13 | 2017-08-18 | 南洋理工大学 | 多层纳米颗粒及其制作方法和使用方法 |
| EP3576751A4 (en) * | 2017-02-01 | 2021-08-04 | ModernaTX, Inc. | RNA ANTI-CANCER VACCINES |
| CN111630173A (zh) * | 2017-10-19 | 2020-09-04 | 库瑞瓦格股份公司 | 新型人工核酸分子 |
| CA3099519A1 (en) * | 2018-05-08 | 2019-11-14 | University Of Florida Research Foundation, Incorporated | Magnetic liposomes and related treatment and imaging methods |
| EP3942050A4 (en) * | 2019-03-19 | 2023-02-22 | Arcturus Therapeutics, Inc. | PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES |
-
2021
- 2021-02-05 EP EP21751192.2A patent/EP4099988A4/en active Pending
- 2021-02-05 JP JP2022547802A patent/JP2023512707A/ja active Pending
- 2021-02-05 US US17/797,810 patent/US20230096704A1/en active Pending
- 2021-02-05 WO PCT/US2021/016925 patent/WO2021158996A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Takakura et al. | Strategies for persistent retention of macromolecules and nanoparticles in the blood circulation | |
| Zhang et al. | A comprehensive review of small interfering RNAs (siRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy | |
| LI et al. | Surface‐modified LPD nanoparticles for tumor targeting | |
| Zhang et al. | Recent advances in exosome-mediated nucleic acid delivery for cancer therapy | |
| Buyens et al. | Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design | |
| Liu et al. | Dendrimers as non-viral vectors for siRNA delivery | |
| Merkel et al. | Nonviral siRNA delivery to the lung: Investigation of PEG− PEI polyplexes and their in vivo performance | |
| US9574210B2 (en) | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof | |
| JP2025138644A5 (https=) | ||
| Rahman et al. | Nucleic acid-loaded lipid-polymer nanohybrids as novel nanotherapeutics in anticancer therapy | |
| JP2011503070A (ja) | 全身遺伝子送達のための自己構築型ミセル様ナノ粒子 | |
| CN115141829A (zh) | 一种基因线路、rna递送系统及其应用 | |
| Lin et al. | Sterically polymer-based liposomal complexes with dual-shell structure for enhancing the siRNA delivery | |
| Chen et al. | Nanoparticle‐mediated siRNA delivery and multifunctional modification strategies for effective cancer therapy | |
| Soleimani et al. | CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice | |
| Magalhaes et al. | RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers | |
| CN119074950A (zh) | 一种增强mRNA-LNP组织靶向递送的方法 | |
| Wang et al. | Intelligent nanoparticles with pH-sensitive co-delivery of temozolomide and siEGFR to ameliorate glioma therapy | |
| JPWO2021158996A5 (https=) | ||
| Shcharbin et al. | Recent advances in multifunctional dendrimer‐based complexes for cancer treatment | |
| Li et al. | Lipid-based vehicles for siRNA delivery in biomedical field | |
| CN119405823B (zh) | 一种基于g四链体rna的蛋白降解靶向嵌合体及其制备方法与应用 | |
| JPWO2021202772A5 (https=) | ||
| JPWO2021138600A5 (https=) | ||
| JPWO2020002540A5 (https=) |